Sotevtamab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Sotevtamab Usage And Synthesis

Uses

Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research[1][2][3].

in vivo

References

[1] Gilles Tremblay, et al. Abstract 1467: AB-16B5, a therapeutic monoclonal antibody against human clusterin that blocks the epithelial-to-mesenchymal transition. Cancer Res 15 April 2010; 70 (8_Supplement): 1467.
[2] Cristiano Ferrario, et al. Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies. Cancer Res 1 July 2017; 77 (13_Supplement): CT098.
[3] Gilles B. et al. Pre-clinical evaluation of AB-16B5, a monoclonal antibody specific for tumor-associated sCLU, demonstrates therapeutic potential as an inhibitor of EMT in prostate, pancreatic and lung cancer. Cancer Res 15 April 2011; 71 (8_Supplement): LB–33.

Sotevtamab(2411526-47-9)Related Product Information

• Zanidatamab
• Telimomabaritox
• Retifanlimab
• Research Grade Inotuzumabc (DHD38502)
• Perakizumab
• Detumomab
• OregovoMab
• Idarucizumab
• Zimberelimab
• Morolimumab